CNBC's Meg Tirrell reports the FDA has expanded Pfizer's Covid-19 booster eligibility for kids aged 5 to 11.
The at-home testing market is bigger than just Covid tests. The emerging marketplace of consumer-initiated lab testing may be worth over $2 billion by 2025, according to Quest Diagnostics. Tests can calculate anything from fertility to STDs using the same testing infrastructure built by the likes of diagnostics companies as well as some of the top laboratories in the nation. Watch the video above to learn more about how this industry works.
At-home rapid Covid tests have been in short supply during the latest wave of infections. But the White House has made it clear that those tests — sold over-the-counter at drugstores — will be critical when it comes to keeping the economy running. Find out how the U.S. fell behind on its at-home testing strategy, and what's being done to fix it.
The U.S.'s approval of Biogen's Alzheimer's drug Aduhelm was heralded as a triumph in the fight against the memory-robbing disease. But so far, Biogen has reported only a fraction of the expected revenue for Aduhelm. Patients and physicians have been torn over the drug's murky clinical data and its high price tag. Aduhelm's lackluster launch has been costly, forcing Biogen to take measures to keep the drug afloat.
The Food and Drug Administration has granted emergency authorization to Pfizer's Covid treatment pill, a major milestone that promises to revolutionize the fight against the virus. CNBC's Meg Tirrell reports.
The Wall Street Journal is reporting that the FDA is laying the ground work for a quick review of omicron-targeted vaccines and drugs, if needed.